July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Relationship between sub retinal fluid (SRF) and vision outcomes in eyes with neovascular age-related macular degeneration (nAMD) in the HARBOR trial
Author Affiliations & Notes
  • Srinivas R Sadda
    Ophthalmology, Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California, United States
    Doheny Eye Institute, Los Angeles, California, United States
  • Avanti Ghanekar
    Genentech Inc., California, United States
  • Lauren Hill
    Genentech Inc., California, United States
  • Shamika Gune
    Genentech Inc., California, United States
  • Footnotes
    Commercial Relationships   Srinivas Sadda, Allergan (F), Allergan (C), Carl Zeiss Meditec (F), Centervue (C), Genentech (F), Genentech (C), Heidelberg (C), Iconic (C), Novartis (C), Optos (F), Optos (C), Thrombogenics (C), Topcon (R); Avanti Ghanekar, Genentech (E); Lauren Hill, Genentech (E); Shamika Gune, Genentech (E)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5189. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Srinivas R Sadda, Avanti Ghanekar, Lauren Hill, Shamika Gune; Relationship between sub retinal fluid (SRF) and vision outcomes in eyes with neovascular age-related macular degeneration (nAMD) in the HARBOR trial. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5189.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the relationship between the presence or absence of residual SRF and best-corrected visual acuity (BCVA) of 20/40 or better (≥69 letters on the Early Treatment Diabetic Retinopathy Study scale [ETDRS]) in the HARBOR study (NCT00891735) of ranibizumab in nAMD.

Methods : Treatment-naïve patients with nAMD were randomized to ranibizumab 0.5 mg or 2.0 mg administered monthly or pro re nata. This analysis included eyes with SRF at baseline (defined as screening, baseline, or week 1) (N = 785; all treatment arms pooled). Analysis outcomes were BCVA and BCVA ≥69 letters in study eyes with SRF (at baseline, month [M] 12, and M24) as a covariate. The post baseline analysis was adjusted by baseline BCVA values.

Results : Among eyes with SRF at baseline, 22.0% and 20.3% had residual SRF at M12 and M24, respectively. Mean BCVA (letters, 95% confidence interval [CI]) at baseline was higher in eyes with residual SRF at M12 (58.8; 57.2, 60.4) and M24 (59.3; 57.8, 60.8) compared with eyes with resolved SRF at M12 (53.5; 52.4, 54.5) and M24 (53.5; 52.5, 54.5). The odds of achieving BCVA ≥69 letters (Snellen equivalent: 20/40 or better) for eyes with residual SRF vs resolved SRF were similar at M12 (Odds ratio: 1.07; 95% CI: 0.72, 1.59) and M24 (1.14; 0.77, 1.68), respectively, after adjusting for baseline BCVA values. In eyes with residual SRF, the presence of SRF in the central subfield tended to have higher odds of obtaining BCVA ≥69 at M12 (1.81; 0.81, 4.04) and M24 (1.33; 0.59, 3.02), however, the effect was not significant.

Conclusions : In the HARBOR population, eyes with residual SRF at M12 and M24 had better baseline BCVA than those with resolved SRF at the same time points. Furthermore, there was no significant difference between eyes with residual SRF vs resolved SRF in attaining a BCVA of 20/40 or better (≥69 letters) at M12 and M24. As the presence of residual SRF does not appear detrimental to vision outcomes at M12 or M24, further investigation may be warranted to define the optimal SRF control needed to achieve the best long-term vision outcomes in nAMD and understand the relationship of SRF to choroidal neovascularization structure and the integrity of various retinal layers.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×